532 Seventeen Mile Rocks Rd Sinnamon Park QLD, 4073, Australia Ph: (07) 3186 6740 www.xingtech.com.au enquiries@xingtech.com.au



June 16th, 2021

Thermo Fisher Scientific (NYSE: TMO), the world leader in serving science, have signed a letter of support to express their potential interest in XING's XavTrap® platform, and their desire to collaborate with XING on an initial proof-of-concept study on reagents of interest to Thermo Fisher Scientific.

Thermo Fisher Scientific is interested in evaluating XavTrap® protein constructs as detection reagents for target antigens in commonly used research use only (RUO) applications, such as Western Blotting, immunofluorescence, and flow cytometry. TMO is also interested in exploring opportunities with the in-built XavTrap® tags for immunoprecipitations and Western blotting applications.

Thermo Fisher Scientific thinks the XavTrap® platform may have the potential to address key technical and market opportunities not currently served by antibodies and could provide scalable business opportunities across TMO's global research and diagnostic markets.

XING is excited about this collaboration with Thermo Fisher Scientific, and the potential to bring the XavTrap® technology into the hands of scientists and medical researchers around the world.

Dr. Paul Mainwaring MBBS(Syd) MD(Lond) FRACP Co-Founder, CEO & Chairman

www.xingtech.com.au

XINGnostics Inc.





